Initial Real-World Experience With PCSK-9 Inhibitors in Current Indications for Reimbursement in Spain

Rev Esp Cardiol (Engl Ed). 2019 Nov;72(11):968-970. doi: 10.1016/j.rec.2019.03.008. Epub 2019 May 16.
[Article in English, Spanish]
No abstract available

Publication types

  • Multicenter Study
  • Observational Study

MeSH terms

  • Adult
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Anticholesteremic Agents / therapeutic use
  • Cholesterol, LDL / blood*
  • Cholesterol, LDL / drug effects
  • Female
  • Humans
  • Hyperlipidemia, Familial Combined / blood
  • Hyperlipidemia, Familial Combined / drug therapy*
  • Male
  • Middle Aged
  • Proprotein Convertase 1 / antagonists & inhibitors*
  • Proprotein Convertase 1 / blood
  • Retrospective Studies
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal, Humanized
  • Anticholesteremic Agents
  • Cholesterol, LDL
  • PCSK1 protein, human
  • Proprotein Convertase 1
  • evolocumab
  • alirocumab